The increased expression of TYK2 gene indicated worse overall survival outcomes in ACC, LAML, and PRAD, while the increased expression of TYK2 gene indicated better overall survival outcomes in PAAD. The gene discussed is TYK2; the disease is prostate adenocarcinoma.